Single Cell RNA-Seq and Machine Learning Reveal Novel Subpopulations in Low-Grade Inflammatory Monocytes With Unique Regulatory Circuits

Subclinical doses of LPS (SD-LPS) are known to cause low-grade inflammatory activation of monocytes, which could lead to inflammatory diseases including atherosclerosis and metabolic syndrome. Sodium 4-phenylbutyrate is a potential therapeutic compound which can reduce the inflammation caused by SD-...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 627036
Main Authors Lee, Jiyoung, Geng, Shuo, Li, Song, Li, Liwu
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Research Foundation 23.02.2021
Frontiers Media S.A
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Subclinical doses of LPS (SD-LPS) are known to cause low-grade inflammatory activation of monocytes, which could lead to inflammatory diseases including atherosclerosis and metabolic syndrome. Sodium 4-phenylbutyrate is a potential therapeutic compound which can reduce the inflammation caused by SD-LPS. To understand the gene regulatory networks of these processes, we have generated scRNA-seq data from mouse monocytes treated with these compounds and identified 11 novel cell clusters. We have developed a machine learning method to integrate scRNA-seq, ATAC-seq, and binding motifs to characterize gene regulatory networks underlying these cell clusters. Using guided regularized random forest and feature selection, our method achieved high performance and outperformed a traditional enrichment-based method in selecting candidate regulatory genes. Our method is particularly efficient in selecting a few candidate genes to explain observed expression pattern. In particular, among 531 candidate TFs, our method achieves an auROC of 0.961 with only 10 motifs. Finally, we found two novel subpopulations of monocyte cells in response to SD-LPS and we confirmed our analysis using independent flow cytometry experiments. Our results suggest that our new machine learning method can select candidate regulatory genes as potential targets for developing new therapeutics against low grade inflammation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
SC0020358
USDOE Office of Science (SC), Biological and Environmental Research (BER)
Edited by: Guo-Chang Fan, University of Cincinnati, United States
This article was submitted to Inflammation, a section of the journal Frontiers in Immunology
Reviewed by: Chuanfu Li, East Tennessee State University, United States; Haichao Wang, Feinstein Institute for Medical Research, United States; Xiang-An Li, University of Kentucky, United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.627036